Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 75Genitourinary 40Thoracic 18Other hematologic neoplasm 17Sarcoma 16Breast 16Dermatologic 11Head & Neck 9CNS 9Endocrine 8Lymphoid 7Gynecologic 7Tumor-Agnostic 4Myeloid 4Plasma cell 3NET 2Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 2Vipoma 1Somatostatinoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1

Interventions

Everolimus 18lanreotide 7Octreotide 7pembrolizumab 6Sunitinib 6Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3pasireotide 3lenvatinib 3arginyllysine 3Temozolomide 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Sorafenib × NET × Clear all
NCT00605566 2019-02-19

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

University Health Network, Toronto

Phase 2 Completed
22 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡